期刊文献+

^(125)I-白蛋白融合干扰素α2b大鼠体内排泄研究 被引量:1

Excretion of ^(125)I-HSA-IFNα2b Fusion Protein in Rats
下载PDF
导出
摘要 为研究125I-白蛋白融合干扰素α2b大鼠体内排泄行为,利用氯胺-T法制备了125I-白蛋白融合干扰素α2b,其标记率为82.72%,放化纯度为95.53%,放射性比活度为0.26MBq/μg。体外WISH/VSV系统抗病毒活性比较分析表明,白蛋白融合干扰素α2b和125I-白蛋白融合干扰素α2b具有相近的抗病毒活性。SD大鼠皮下注射125I-白蛋白融合干扰素α2b后,0~6、6~12、12~24、24~48、48~96、96~192和192~300h7个不同时段的尿、粪的放射性分析结果表明,125I-白蛋白融合干扰素α2b主要通过肾脏排泄,部分可通过粪便排泄,300h时尿、粪中平均累积排泄率分别为80.10%和16.00%;0~1、1~2、2~4、4~6、6~12、12~24和24~30h7个不同时段的胆汁的放射性分析结果表明,125I-白蛋白融合干扰素α2b也可通过肝脏代谢后经胆汁排泄,但这不是它的主要排泄途径,30h时,胆汁中的平均累积排泄率仅为1.61%。 12SI-HSA-IFNα2b was prepared with Ch-T method. The labeling yield is 82.72%, the radiochemical purity is 95.53%, and the specific activity is 0.26 MBq/μg. The antiviral activities of 125I-HSA-IFNα2b are almost same as HSA-IFNα2b analyzed with WlSH/VSV system in vitro. After SD rats injected with 125I-HSA-IFNα2b subcu- taneously, the radioactivity in urine and faeces in seven different periods of 0-6, 6-12, 12-24, 24-48, 48-96, 96-192 and 192-300 h shows that 125I-HSA-IFNα2b is excreted mainly by kidneys, partly by diachorema, and average accumulation excretory rates of 300 h in urine and feces are 80.10% and 16.00%, respectively; the radioactivity in bile in seven periods of 0-1, 1-2, 2-4, 4-6, 6-12, 12-24 and 24-30 h shows that 125I-HSA- IFNα2b also can be excreted by bile after being metabolized by liver, and average accu- mulation excretory rate of 30 h in bile is only 1.61%.
出处 《原子能科学技术》 EI CAS CSCD 北大核心 2010年第2期171-174,共4页 Atomic Energy Science and Technology
基金 国家自然科学基金资助项目(30670589) 卫生部科研基金资助项目(wkj2006-2-5) 江苏省"六大人才高峰"计划B类资助项目(06-B-026) 江苏省医学重点人才项目(RC2007097)
关键词 白蛋白融合干扰素α2b 125I- 排泄 HSA-IFNα2b 12sI excretion
  • 相关文献

参考文献6

  • 1KOZLOWSKI A, HARRIS J M. Improvements in protein PEGylation: Pegylated interferons for treatment of hepatitis C [J]. Journal of Controlled Release, 2001, 72(1-3): 217-224.
  • 2RAMON J, SAEZ V, BAEZ R, et al. PEGylated interferon-alpha2b: A branched 40K polyethy lene glycol derivative[J]. Pharm Res, 2005, 22 (8): 1 374-1 386.
  • 3MAGER D E, NEUTEBOOM B, JUSKO W J Pharmacokinetics and pharmacodynamics of PE Gylated IFN-beta la following subcutaneous ad ministration in monkeys[J]. Pharm Res, 2005 22(1): 58-61.
  • 4SUNG C, NARDELLI B, LaFLEUR D W, et al. An IFN-beta-albumin fusion protein that dis plays improved pharmacokinetie and pharmacodynamic properties in nonhuman primates[J]. J Interferon Cytokine Res, 2003, 23(1): 25-36.
  • 5HUNTER W M, GREENWOOD F C. Preparation of iodine-131 labelled human growth hormone of high specific activity[J]. Nature, 1962, 194: 495-496.
  • 6顾晓波,张荣军,杨健良,蒋孟军,周尧远,蔡刚明,张波,曹国宪.同位素法体内示踪HSA-IFN-α2b的方法学研究[J].同位素,2008,21(4):220-225. 被引量:1

二级参考文献6

  • 1MAGER DE, NEUTEBOOM B, JUSKO WJ. Pharmacokinetics and Pharmacodynamics of PEGy-lated IFN-beta 1a Following Subcutaneous Administration in Monkeys[J]. Pharm Res, 2005, 22: 58-61.
  • 2SUNG C, NARDELLI B, LAFLEUR DW, et al. An IFN-beta-albumin Fusion Protein That Displays Improved Pharmaeokinetie and Pharmaeodynamic Properties in Nonhuman Primates[J]. J Interferon Cytokine Res, 2003, 23:25-36.
  • 3国家药典委员会.中华人民共和国药典:2005版,第三部[M].北京:化学工业出版社,2005:附录XC.
  • 4KOZLOWSKI A, HARRIS JM. Improvements in Protein PEGylation: Pegylated Interferons for Treatment of Hepatitis C[J]. J Control Release, 2001, 72:217-224.
  • 5RAMON J, SAEZ V, BAEZ R, et al. PEGylated Interferon-α2b: a Branched 40K Polyethylene Glycol Derivative[J]. Pharm Res, 2005, 22:1 374- 1 386.
  • 6谭成,万卫星,张荣军,张莲芬,韩玉珉,金坚.重组水蛭素与血栓前体关系的研究[J].核技术,2000,23(5):343-346. 被引量:12

同被引文献14

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部